Analysts: Expedia Faces Intense Competition and 3 Other Research Notes to Check Out
Expedia (NASDAQ:EXPE): Deutsche Bank downgraded Expedia to Hold from Buy, citing recent management changes at Hotels.com and the firm’s quarterly checks that indicate the company continues to face challenges of intense competition and inflating customer acquisition costs. Deutsche Bank lowered its price target for Expedia shares to $51 from $66.
JPMorgan (NYSE:JPM): Citigroup raised its price target for JPMorgan shares to $66 from $62, saying the company’s core third-quarter results looked good. The firm maintains a Buy rating on JPMorgan stock.
Coach (NYSE:COH): Canaccord downgraded Coach to Hold from Buy and lowered estimates due to deteriorating traffic trends, competitor market share gains, and limited near-term visibility. The firm lowered its price target for Coach shares to $62 from $65.
Gilead (NASDAQ:GILD): Leerink believes the liver transplant setting is an under-appreciated near-term opportunity for sofosbuvir sales. Accordingly, the firm added $1 billion to its 2014 sofosbuvir estimate of $2 billion, which the analyst notes was already above the consensus of $1.8 billion, and raised its price target for Gilead shares to $77 from $70. Leerink reiterates an Outperform rating on the stock.